Skip to main content
. 2020 Oct 9;105(12):2738–2745. doi: 10.3324/haematol.2019.242891

Table 1.

Key characteristics of selected studies of discontinuation of tyrosine kinase inhibitor therapy.

graphic file with name 1052738.tab1.jpg